by | Mar 11, 2024 | Uncategorized
Source: CureToday articles The BCMA protein has become the primary target for treating multiple myeloma, resulting in longer survival and more manageable side effects. Read More
by | Mar 10, 2024 | Uncategorized
Source: CureToday articles This poem was written in hope that those experiencing multiple myeloma, or other cancers, will find solace in knowing that advancements in treatments are being made every day, and a positive attitude with caregiver acceptance and support...
by | Mar 7, 2024 | Uncategorized
The combination of belantamab mafodotin, pomalidomide and dexamethasone extended PFS compared with standard care for patients with relapsed or refractory multiple myeloma, according to a topline data announcement.Belantamab mafodotin (Blenrep, GSK) is an antibody-drug...
by | Mar 7, 2024 | Uncategorized
Source: ASCO Daily News Drs. John Sweetenham and Shaji Kumar discuss the emergence of CAR T-cell therapy for multiple myeloma, its benefits and challenges for patients, and its potential role earlier in the treatment of disease. TRANSCRIPT Dr. John Sweetenham: Hello,...
by | Feb 23, 2024 | Uncategorized
The FDA announced its final decision to rescind approval of melphalan flufenamide, citing safety concerns.The agency approved melphalan flufenamide (Pepaxto, Oncopeptides) for use in combination with dexamethasone to treat certain patients with multiple myeloma in...
by | Feb 23, 2024 | Uncategorized
Source: CureToday articles Most patients with relapsed or refractory multiple myeloma responded to treatment with the CAR-T cell therapy, Carvykti, according to a small study. Read More
